Articles 2020

DateTitle
16/09/2020Zelira Therapeutics (ASX:ZLD) launches Zenivol in Australia
16/09/2020Zelira Therapeutics’ insomnia treatment gets TGA tick
16/09/2020Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme
15/09/2020Medicinal cannabis trial could help retired AFL players manage chronic pain
08/09/2020Zelira Therapeutics forms subsidiary to launch hemp-derived oral care products in the USA
24/08/2020Proactive – Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers
20/08/2020Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers
17/08/2020Zelira Therapeutics MD shows faith in medical cannabis strategy with placement participation
07/08/2020Proactive – Three medical cannabis companies in focus at Proactive’s webinar on August 11
16/07/2020Starts at 60 – Suffer from chronic pain? Medicinal cannabis could be the answer
14/07/2020TechInvest – Zelira obtains key data in cannabis dose escalation study
14/07/2020The Market Herald – Zelira Therapeutics (ASX:ZLD) confirms ZTL-103 is safe and well-tolerated
14/07/2020Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints
14/07/2020Stockhead – Pot stock Zelira Therapeutics successfully passes another Phase I clinical trial
28/05/2020Benzinga Article: A Medicinal Cannabis Company That’s Conducting Clinical Research On Autism, Insomnia, And More
23/04/2020Q&A with Osagie Imasogie, Chairman, Zelira Therapeutics: Zelira Phase 1b/2a Insomnia Clinical Trial Results
09/04/2020Biotech Daily – Zelira: Marijuana ZLT-101 ‘Effective For Insomnia’
29/03/2020Stockhead – Dr Boreham’s Crucible: Zelira’s share price could wake up once sales of its pot-based insomnia drug start